NCT02264990

Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers

A Randomized, Open-Label, Multicenter, Phase 3 Trial Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 595 (actual)
• Sponsor: AbbVie · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the safety and efficacy of veliparib plus carboplatin and paclitaxel versus the Investigator's choice of standard chemotherapy in adults with metastatic or advanced non-squamous non-small cell lung cancer.

Conditions

• Non-squamous Non-small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	Paclitaxel	Administered by Intravenous infusion on Day 1 of each 21-day cycle
DRUG	Carboplatin	Administered by Intravenous infusion on Day 1 of each 21-day cycle
DRUG	Cisplatin	Administered by Intravenous infusion on Day 1 of each 21-day cycle
DRUG	Veliparib	Oral capsule, administered twice daily for 7 days in each 21-day cycle
DRUG	Pemetrexed	Administered by Intravenous infusion on Day 1 of each 21-day cycle

Timeline

• Start date: 2014-09-30
• Primary completion: 2019-11-14
• Completion: 2020-02-21
• First posted: 2014-10-15
• Last updated: 2021-02-26
• Results posted: 2021-02-26

Locations

140 sites across 20 countries: United States, Argentina, Australia, Canada, Czechia, Denmark, Finland, Germany, Hungary, Israel, Japan, Netherlands, New Zealand, Russia, South Africa, South Korea, Spain, Taiwan, Turkey (Türkiye), United Kingdom

Regulatory

• FDA-regulated drug study